Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats

BACKGROUND: Erlotinib (ERL) and Gefitinib (GEF) are considered first line therapy for the management of non-small cell lung carcinoma (NSCLC). Like other tyrosine kinase inhibitors (TKIs), ERL and GEF are mainly metabolized by the cytochrome P450 (CYP450) CYP3A4 isoform and are substrates for transp...

Descripción completa

Detalles Bibliográficos
Autores principales: Almomen, Aliyah, Maher, Hadir M., Alzoman, Nourah Z., Shehata, Shereen M., Alsubaie, Amal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2020
Materias:
Toxicology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518156/
https://www.ncbi.nlm.nih.gov/pubmed/33024629
http://dx.doi.org/10.7717/peerj.9881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518156/
https://www.ncbi.nlm.nih.gov/pubmed/33024629
http://dx.doi.org/10.7717/peerj.9881

Ejemplares similares